Drug intelligence / Profile preview

VS-214

Development stage: Preclinical
Lead developer: Vasa Therapeutics
Modality: Peptides

Overview

VS-214 is a long-acting apelin analog being developed as a peptide therapeutic for the treatment of peripheral arterial disease (PAD) and various rare neuromuscular diseases. Developed by Vasa Therapeutics, it acts as an agonist of the apelin receptor, a G protein-coupled receptor that modulates cardiovascular and musculoskeletal signaling pathways. Preclinical evidence suggests that VS-214 can increase muscle strength and endurance, preserve muscle function, and enhance cardiac output. Its targeted indications include facioscapulohumeral muscular dystrophy (FSHD), spinal muscular atrophy (SMA), spinal cord injury, and sarcopenia. The drug is currently in preclinical development, with clinical trials expected to commence in 2026.

Other names: long-acting apelin analogapelin receptor agonist

Targets

APLNR (Apelin receptor)

Beyond the preview

Go deeper on VS-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-214.

Explore the full profile